Qiagen (NYSE:QGEN – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its competitors? We will compare Qiagen to related businesses based on the strength of its dividends, analyst recommendations, valuation, earnings, institutional ownership, profitability and risk.
Profitability
This table compares Qiagen and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Qiagen | 18.19% | 14.70% | 8.58% |
| Qiagen Competitors | -477.84% | 79.93% | -12.81% |
Volatility & Risk
Qiagen has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Qiagen’s competitors have a beta of 0.94, suggesting that their average stock price is 6% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Qiagen | 0 | 11 | 4 | 0 | 2.27 |
| Qiagen Competitors | 960 | 3205 | 5536 | 179 | 2.50 |
Qiagen presently has a consensus price target of $46.34, suggesting a potential downside of 6.00%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 5.43%. Given Qiagen’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Qiagen has less favorable growth aspects than its competitors.
Dividends
Qiagen pays an annual dividend of $0.35 per share and has a dividend yield of 0.7%. Qiagen pays out 19.1% of its earnings in the form of a dividend. As a group, “Life Sciences Tools & Services” companies pay a dividend yield of 8.6% and pay out 44.5% of their earnings in the form of a dividend.
Insider and Institutional Ownership
70.0% of Qiagen shares are owned by institutional investors. Comparatively, 54.0% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 14.8% of shares of all “Life Sciences Tools & Services” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Qiagen and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Qiagen | $2.12 billion | $424.88 million | 26.94 |
| Qiagen Competitors | $2.29 billion | $55.87 billion | -7.35 |
Qiagen’s competitors have higher revenue and earnings than Qiagen. Qiagen is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Summary
Qiagen competitors beat Qiagen on 10 of the 15 factors compared.
Qiagen Company Profile
QIAGEN is a life sciences company that develops technologies used to prepare and analyze biological samples. Its products help researchers and clinicians extract and process DNA, RNA and proteins from samples such as blood, tissue and other biological materials. The company offers laboratory consumables, instruments and software for molecular diagnostics and life sciences research, as well as applications in pharmaceutical research and applied testing. Its portfolio includes sample-preparation kits, molecular testing assays and platforms for PCR, digital PCR and next-generation sequencing.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
